Investor Relations

Takeover offer - Website for further information

Documents

Joint reasoned statement of the Management Board and Supervisory Board

preview

Joint reasoned statement of the Management Board and Supervisory Board
PDF, 988 KB
[ Download ]

FAQ – Frequently asked questions about the Takeover Offer by CREAT Group Corporation, Peking, China

preview

FAQ – Frequently asked questions about the Takeover Offer
PDF, 248 KB
[ Download ]

FAQ – Frequently asked questions about the Takeover Offer by CREAT Group Corporation, Peking, China

1. What are the key details of the takeover offer?

2. How will I receive information on the offer documentation?

3. What are the next steps and when does the acceptance period begin? When can the takeover expect to be completed?

4. When will the Executive Board and the Supervisory Board of BIOTEST AG publish their reasoned opinion? Do I have to wait for this recommendation before I tender my shares?

5. What shall I do with my shares now? How do I accept the takeover offer? Can I sell them via stock exchange and not within the official offer? Who do I have to contact?

6. How will I receive the money from CREAT Group Corporation?

7. Is the offer price of Euro 28.50 per ordinary share and Euro 19.00 per preference share final? Should I tender my shares now or is it better to wait as the price could be revised upwards at the end of the bid phase?

8. Can I revoke my agreement to tender my shares?

9. What happens if I do not accept the offer?

10. What percentage of shares must CREAT Group Corporation acquire in order to successfully complete the takeover?

11. Will BIOTEST announce how many shareholders have already sold their shares?

12. Can I still trade with my shares after I have tendered them?

13. Why was the Annual General Meeting postponed from May 10, 2017?

14. Can I still take part in the Annual General Meeting if I have tendered my shares for sale to the bidder?

15. Are there tax disadvantages for me if I accept or reject the offer?